New Complementary Insulin and GLP-1 Combinations to Achieve HbA1c Targets

ACCREDITATION STATEMENT

This activity has expired and is no longer available for CME credit or ABIM MOC points.

LEARNING OBJECTIVES

Upon completion of this educational activity, learners will be able to:
  • Assess unmet needs and treatment patterns of patients with type 2 diabetes that are not at target
  • Identify and select appropriate glycemic targets tailored to the patient using shared decision making
  • Learn how to select and start new combination options using insulins and GLP-1 that are in development or recently approved to help patients get to goal
  • Gain an understanding of future biologic approaches to treatment
  • Evaluate strategies in the ambulatory setting to mitigate barriers to combination therapy for glucose control

TARGET AUDIENCE

Endocrinologists, internists, endocrine nurses, diabetes educators, researchers, and other allied health professionals

STATEMENT OF INDEPENDENCE

As a provider of continuing medical education (CME) accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society's Special Programs Committee (SPC). The commercial supporter(s) of this activity have no influence over the planning of this CME activity.

DISCLOSURE POLICY

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to The Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.
The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

Athena Philis-Tsimikas, MD: Advisory Board Member, AstraZeneca, Dexcom, Eli Lilly & Co., Novo Nordisk, Sanofi
Daniel Einhorn, MD: Advisory Board Member, Janssen, Lilly USA, LLC, Takeda
George Dailey, MD: Consultant, Sanofi, Novo Nordisk; Speaker, AstraZeneca; Investigator, Eli Lilly & Co., Lexicon, Novo Nordisk, Sanofi
The following faculty reported no relevant financial relationship(s): Alberto Hayek, MD; Jeffrey Sandler, MD

The following SPC member who planned and reviewed content for this activity reported no relevant financial relationships:

Amy Rothberg, MD: Consultant, Novo Nordisk; Speaker, Takeda Pharmaceuticals

The following SPC Committee members reported relevant financial relationships:

Zahid Ahmad, MD: Consultant, Regeneron; Speaker, Amgen, Genzyme
Sarah Berga, MD: Advisory Board, Agile Therapeutics, Noven Pharmaceuticals, Inc., Watson Pharmaceuticals, Teva Pharmaceuticals Industries, Shionogi, Inc.; Consultant, AHC Media, LLC, Shionogi, Inc.
Paresh Dandona, MD, PhD, FRCP: Consultant and Speaker, AstraZeneca, Bristol Myers Squibb, Janssen, Merck, Novo Nordisk
Irl Hirsch, MD: Consultant, Abbott Laboratories, Johnson & Johnson, Roche Diagnostics, Valeritas; Investigator, Sanofi
E. Michael Lewiecki, MD: Consultant, Amgen, Eli Lilly, Merck, Radius Health, AgNovos Healthcare, Theranova; Research Grant Support, Amgen, Eli Lilly, Merck
Lisa Nachtigall, MD: Consultant, Genentech; Consultant and Principal Investigator, Ipsen
Amy Rothberg, MD: Consultant, Novo Nordisk; Speaker, Takeda Pharmaceuticals
Guillermo E. Umpierrez, MD, CDE: Advisory Board and Consultant, Abbott, Boehringer Ingelheim, Merck, Novo Nordisk, Regeneron, Sanofi; Research Grant Support, Boehringer Ingelheim, Merck & Co., Novo Nordisk, Regeneron
The following SPC members reported no relevant financial relationships: John Carmichael, MD; Natalie Cusano, MD; Alan Kelly, MD; Michael S. Irwig, MD; Connie B. Newman, MD
Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

DISCLAIMER

The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the Endocrine Society.

Use of professional judgment:

The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider's examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.

Drugs and dosages:

When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.

POLICY ON UNLABELED/OFF-LABEL USE

The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such "off-label" use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

PRIVACY AND CONFIDENTIALITY STATEMENT

The Endocrine Society will record learner's personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.

ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT

This activity is supported by an educational grant from sanofi-aventis U.S. Inc.

AMA PRA CATEGORY 1 CREDIT™ (CME) AND ABIM MOC POINTS INFORMATION

This activity has expired and is no longer available for CME credit or ABIM MOC points.

SYSTEM REQUIREMENTS

Your system must meet the following requirements:
Computer: with minimum processor and memory as recommended by operating system manufacturer
Operating System: Windows: 7, 8, 10. Macintosh OSX
Internet Browser: consult the detailed system requirements page to determine the browser version required by Adobe Flash on your computer’s operating system.
Players & Plugins: an up-to-date version of Adobe Flash Player
Audio: Functioning sound card with attached speakers installed
Internet Connection: a broadband Internet connection
Please review the detailed system requirements page for more information and troubleshooting steps.
LAST REVIEW DATE: April 2, 2016
ACTIVITY RELEASE DATE: April 2016
ACTIVITY EXPIRATION DATE: April 18, 2017 (date after which this enduring material is no longer certified for AMA PRA Category 1 Credits™ or ABIM MOC points)
For technical assistance or information, please contact support@endosessions.org.
For questions about content or obtaining CME credit or MOC points, please contact the Endocrine Society at education.endocrine.org/contact.